{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:55:10Z","timestamp":1769835310153,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"natural science foundation of zhejiang province","doi-asserted-by":"publisher","award":["LY17H120006"],"award-info":[{"award-number":["LY17H120006"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Breastfeed J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ranibizumab is one of intravitreal anti-vascular endothelial growth factor agents. It is applied in the treatments of choroidal neovascularization, age-related macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion<jats:bold>.<\/jats:bold> Preliminary evidence suggests that intravitreal ranibizumab may enter the plasma and human breast milk in very low-level concentration. As a precaution, breastfeeding is not recommended during the treatment of intravitreal injection of ranibizumab. There are limited data regarding the change of anti-vascular endothelial growth factor concentration in human breast milk after intravitreal injection of ranibizumab, especially in the first 24\u2009h after injection. The purpose of this report is to analyse the concentration change of vascular endothelial growth factor-A in human breast milk with time, in the short term after intravitreal injection of ranibizumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>In June 2018, a 30-year-old patient breastfeeding a six-month-old baby was diagnosed with choroidal neovascularization of left eye in Eye Hospital of Wenzhou Medical University. She received four administrations of 0.5\u2009mg intravitreal injection of ranibizumab of the left eye, and breast milk was collected just before the injection, and 1\u20133, 6, 12, 24, 48, and 72\u2009h after intravitreal injection, and assessed for vascular endothelial growth factor-A concentration. The change in vascular endothelial growth factor-A concentration in human breast milk showed the same trend after each injection, decreasing significantly within 6\u201312\u2009h (about 20\u201330% lower), and increasing to pre-injection level by 24\u2009h after injection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The concentration of vascular endothelial growth factor-A in human breast milk of a mother who continues lactating dropped initially and rose to pre-injection level about 24\u2009h after intravitreal injection of ranibizumab. The data may offer more information to evaluate the impact of anti-vascular endothelial growth factor agent intravitreal injection of lactating mothers and their breastfed infants.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13006-022-00463-y","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T09:04:04Z","timestamp":1648717444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Vascular endothelial growth factor-A level in human breast milk after intravitreal injection of ranibizumab: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Ying","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"issue":"5","key":"463_CR1","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1093\/ajcn\/72.5.1196","volume":"72","author":"P Vuorela","year":"2000","unstructured":"Vuorela P, Andersson S, Carp\u00e9n O, Ylikorkala O, Halmesm\u00e4ki E. Unbound vascular endothelial growth factor and its receptors in breast, human milk, and newborn intestine. Am J Clin Nutr. 2000;72(5):1196\u2013201.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"463_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1006\/cyto.2002.1032","volume":"18","author":"S Nishimura","year":"2002","unstructured":"Nishimura S, Maeno N, Matsuo K, Nakajima T, Kitajima I, Saito H, et al. Human lactiferous mammary gland cells produce vascular endothelial growth factor (VEGF) and express the VEGF receptors, Flt-1 AND KDR\/Flk-1. Cytokine. 2002;18(4):191\u20138.","journal-title":"Cytokine"},{"key":"463_CR3","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1203\/00006450-199905010-00007","volume":"45","author":"C Siafakas","year":"1999","unstructured":"Siafakas C, Anatolitou F, Fusunyan R, Walker W, Sanderson I. Vascular endothelial growth factor (VEGF) is present in human breast milk and its receptor is present on intestinal epithelial cells. Pediatr Res. 1999;45:652\u20137.","journal-title":"Pediatr Res"},{"issue":"1","key":"463_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/08977194.2020.1792469","volume":"38","author":"K Dangat","year":"2020","unstructured":"Dangat K, Khaire A, Joshi S. Cross talk of vascular endothelial growth factor and neurotrophins in mammary gland development. Growth Factors. 2020;38(1):16\u201324.","journal-title":"Growth Factors"},{"issue":"4","key":"463_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1124\/pr.56.4.3","volume":"56","author":"A Hoeben","year":"2004","unstructured":"Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56(4):549\u201380.","journal-title":"Pharmacol Rev"},{"key":"463_CR6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176:1248\u201364.","journal-title":"Cell"},{"key":"463_CR7","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3389\/fphar.2019.01363","volume":"10","author":"NJY Yeo","year":"2019","unstructured":"Yeo NJY, Chan EJJ, Cheung C. Choroidal neovascularization: mechanisms of endothelial dysfunction. Front Pharmacol. 2019;10:1363.","journal-title":"Front Pharmacol"},{"issue":"8","key":"463_CR8","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1097\/IAE.0000000000001744","volume":"38","author":"T Lai","year":"2018","unstructured":"Lai T, Staurenghi G, Lanzetta P, Holz F, Melissa Liew SH, Desset-Brethes S, et al. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina. 2018;38(8):1464\u201377.","journal-title":"Retina"},{"issue":"3","key":"463_CR9","first-page":"138","volume":"75","author":"A Stepanov","year":"2019","unstructured":"Stepanov A, St\u0159edov\u00e1 M, Dusov\u00e1 J, Jir\u00e1skov\u00e1 N, Studni\u010dka J. Ranibizumab for the treatment of choroidal neovascularization due to cause other than age related macular degeneration. Cesk Slov Oftalmol. 2019;75(3):138\u201344.","journal-title":"Cesk Slov Oftalmol"},{"key":"463_CR10","unstructured":"Novartis Pharmaceuticals Canada. Product monograph: Lucentis (ranibizumab injection). https:\/\/www.ask.novartispharma.ca\/download.htm?res=lucentis_scrip_e.pdf&resTitleId=795. Accessed 21 Dec 2021."},{"issue":"9","key":"463_CR11","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1001\/archophthalmol.2012.112","volume":"130","author":"C Ehlken","year":"2012","unstructured":"Ehlken C, Martin G, Stahl A, Agostini HT. Reduction of vascular endothelial growth factor a in human breast milk after intravitreal injection of bevacizumab but not ranibizumab. Arch Ophthalmol. 2012;130(9):1226\u20137.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"463_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ophtha.2019.08.022","volume":"127","author":"V Juncal","year":"2020","unstructured":"Juncal V, Paracha Q, Bamakrid M, Francisconi C, Farah J, Kherani A, et al. Ranibizumab and aflibercept levels in breast milk after intravitreal injection. Ophthalmology. 2020;127(2):278\u201380.","journal-title":"Ophthalmology"},{"issue":"10","key":"463_CR13","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1021\/mp500160v","volume":"11","author":"J Yang","year":"2014","unstructured":"Yang J, Wang X, Fuh G, Yu L, Wakshull E, Khosraviani M, et al. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor a. Mol Pharm. 2014;11(10):3421\u201330.","journal-title":"Mol Pharm"},{"key":"463_CR14","doi-asserted-by":"crossref","first-page":"898207","DOI":"10.1155\/2012\/898207","volume":"2012","author":"T Kubota","year":"2012","unstructured":"Kubota T, Kiuchi Y, Sheridan C. Anti-vascular endothelial growth factor agents for ocular angiogenesis and vascular permeability. J Ophthalmol. 2012;2012:898207.","journal-title":"J Ophthalmol"},{"issue":"10","key":"463_CR15","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"R Avery","year":"2017","unstructured":"Avery R, Castellarin A, Steinle N, Dhoot D, Pieramici D, See R, et al. Systemic pharmacokinetics and pharmacodynamics of aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37(10):1847\u201358.","journal-title":"Retina"},{"issue":"8","key":"463_CR16","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1097\/IAE.0000000000000517","volume":"35","author":"T McFarland","year":"2015","unstructured":"McFarland T, Rhoads A, Hartzell M, Emerson G, Bhavsar A, Stout J. Bevacizumab levels in breast milk after long-term intravitreal injections. Retina. 2015;35(8):1670\u20133.","journal-title":"Retina"}],"container-title":["International Breastfeeding Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13006-022-00463-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13006-022-00463-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13006-022-00463-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T09:15:49Z","timestamp":1648718149000},"score":1,"resource":{"primary":{"URL":"https:\/\/internationalbreastfeedingjournal.biomedcentral.com\/articles\/10.1186\/s13006-022-00463-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["463"],"URL":"https:\/\/doi.org\/10.1186\/s13006-022-00463-y","relation":{},"ISSN":["1746-4358"],"issn-type":[{"value":"1746-4358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"20 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We obtained written consent from the participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participat"}},{"value":"Written informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}